Price
$7.51
Decreased by -2.72%
Dollar volume (20D)
10.21 M
ADR%
4.56
Earnings report date
Feb 26, 2025
Shares float
547.94 M
Shares short
3.83 M [0.70%]
Shares outstanding
257.44 M
Market cap
7.13 B
Beta
0.69
Price/earnings
35.00
20D range
6.83 8.80
50D range
6.83 9.96
200D range
5.68 9.96

Grifols,S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.

The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.

In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug.

Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.

Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.

It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.

The company was founded in 1909 and is headquartered in Barcelona, Spain.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 7, 24 0.17
Increased by +54.55%
0.24
Decreased by -29.17%
Jul 30, 24 0.15
Decreased by -9.04%
0.21
Decreased by -28.57%
May 16, 24 0.07
Increased by +59.82%
0.15
Decreased by -53.33%
Feb 29, 24 0.14
Increased by +118.41%
0.22
Decreased by -36.36%
Nov 2, 23 0.11
Increased by +N/A%
0.22
Decreased by -50.00%
Jul 27, 23 0.16
Increased by +24.92%
0.20
Decreased by -17.18%
May 15, 23 0.04
Increased by +N/A%
0.16
Decreased by -72.47%
Feb 28, 23 0.06
Decreased by -43.47%
0.15
Decreased by -57.61%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 1.79 B
Increased by +12.24%
51.69 M
Decreased by -13.19%
Increased by +2.88%
Decreased by -22.65%
Jun 30, 24 1.82 B
Increased by +9.28%
14.84 M
Decreased by -75.28%
Increased by +0.82%
Decreased by -77.38%
Mar 31, 24 1.63 B
Decreased by -5.08%
21.42 M
Increased by +6.72%
Increased by +1.32%
Increased by +12.44%
Dec 31, 23 1.77 B
Increased by +3.32%
55.99 M
Increased by +178.99%
Increased by +3.16%
Increased by +170.03%
Sep 30, 23 1.60 B
Increased by +3.66%
59.54 M
Increased by +33.63%
Increased by +3.73%
Increased by +28.91%
Jun 30, 23 1.66 B
Increased by +7.81%
60.03 M
Decreased by -33.54%
Increased by +3.61%
Decreased by -38.36%
Mar 31, 23 1.71 B
Increased by +42.94%
20.07 M
Increased by +151.40%
Increased by +1.17%
Increased by +135.96%
Dec 31, 22 1.71 B
Increased by +N/A%
20.07 M
Increased by +N/A%
Increased by +1.17%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY